Medium to long term follow up of a large UK cohort of active monitoring of patients
BAUS ePoster online library. Bennett A. 06/30/16; 132005; P10-5
Mr. Adam Bennett
Mr. Adam Bennett
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
P10-5

Introduction

Active surveillance is now an established part of the management of patients with low risk localised prostate cancer. However, long term follow-up data for it is still lacking.

Methods

We reviewed a prospectively collected database of active monitoring (AM) patients within our institution from February 1997 to March 2014. Age, PSA, Gleason grade and D’Amico classification at presentation were reviewed. Time to treatment and survival were assessed.

Results

506 patients were included with a median follow up of 5.95 years (range 0.83- 18.8 years). Median age was 68 years (range 46 - 92) and median PSA was 7.6ng/ml  (range 0.4-35.4) at presentation. 85.4% had Gleason 6 and 14.6% Gleason 7 . 63.4% were D’Amico low risk, 32.4% intermediate risk and 4% high risk. Overall, 42.3% of patients received treatment. Median time to treatment was 2.5 years. Percentage of patients receiving treatment at 0-5 years follow-up was 33.6%, 5-10 years follow-up was 40.7% and >10 years  was 42.3%. Of these treated patients, 8% chose to withdraw from AM and the remainder had treatment based on PSA rise and/or a combination of grade/volume/stage progression.

A total of 76 patients died (15%). Overall survival at 5, 10 and 15 years was 91.6%, 81.7% and 71.6% respectively. Disease specific survival at 5, 10 and 15 years was 99.4%, 97.8% and 90.0% respectively.

Conclusion

Overall, treatment and survival rates for our cohort are similar to other published data with similar follow-up times.

 

 

P10-5

Introduction

Active surveillance is now an established part of the management of patients with low risk localised prostate cancer. However, long term follow-up data for it is still lacking.

Methods

We reviewed a prospectively collected database of active monitoring (AM) patients within our institution from February 1997 to March 2014. Age, PSA, Gleason grade and D’Amico classification at presentation were reviewed. Time to treatment and survival were assessed.

Results

506 patients were included with a median follow up of 5.95 years (range 0.83- 18.8 years). Median age was 68 years (range 46 - 92) and median PSA was 7.6ng/ml  (range 0.4-35.4) at presentation. 85.4% had Gleason 6 and 14.6% Gleason 7 . 63.4% were D’Amico low risk, 32.4% intermediate risk and 4% high risk. Overall, 42.3% of patients received treatment. Median time to treatment was 2.5 years. Percentage of patients receiving treatment at 0-5 years follow-up was 33.6%, 5-10 years follow-up was 40.7% and >10 years  was 42.3%. Of these treated patients, 8% chose to withdraw from AM and the remainder had treatment based on PSA rise and/or a combination of grade/volume/stage progression.

A total of 76 patients died (15%). Overall survival at 5, 10 and 15 years was 91.6%, 81.7% and 71.6% respectively. Disease specific survival at 5, 10 and 15 years was 99.4%, 97.8% and 90.0% respectively.

Conclusion

Overall, treatment and survival rates for our cohort are similar to other published data with similar follow-up times.

 

 

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies